NCE-1 Intelligence & Market Opportunity

Rezlidhia

Olutasidenib

Anticancer

Oral Capsule

Approval Date

01-Dec-22

NCE-1 Date

01-Dec-26

NCE Date

01-Dec-27

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.2214

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

101

Molecule profile

Details & specifications

Molecule

Olutasidenib

Innovator

RIGEL PHARMACEUTICALS, INC.

Dosage Form

Oral Capsule

Strength

150 mg

Therapeutic Category

Anticancer

Usage

To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.